News, Events & Resources
There’s a lot happening at Melinta. We are the company of the moment and enterprise of the future. Join us in realizing our vision — this is our story, and it’s going to be legendary.
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
January 24, 2023Press ReleaseFDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and invasive...
The Antimicrobials Working Group Announces Appointment of Christine Ann Miller as Board Chair
January 17, 2023Press ReleaseWASHINGTON, Jan. 17, 2023 /PRNewswire/ -- The Antimicrobials Working Group (AWG), an industry-led coalition of antimicrobial companies, announced today the...
Cidara Therapeutics and Melinta Therapeutics Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet
November 28, 2022Press Release Publication details the efficacy and safety of rezafungin dosed once-weekly versus the current of care dosed once-daily Rezafungin PDUFA target action date is...